The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC. The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens. The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation. The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo. The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades. The panel explores our understanding of nccRCC, including classification, molecular distinctions, and prognostic criteria.